Lan T. Tran

EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA.

Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA.

Los Angeles Biomedical Research Institute at Harbor-UCLA, also known as the Lundquist Institute, is a non-profit research organization located in Torrance, CA. The institute has also started working on a vaccine for the urgent fungal threat, Candida auris, which is spreading at an alarming rate throughout healthcare facilities in the US and is resistant to several antifungal drugs. The institute focuses on biomedical research, clinical trials, and community outreach programs. The institute has various research theme groups and researchers working on different projects, including the Institute for Translational Genomics and Population Sciences, which contributes to new research in genomics. The Lundquist Institute has received several grants and gifts for its research, including a $1.50 million gift from Farima and Joseph Czyzyk for the Diagnostic and Wellness Center. The CEO of the private company is David I. Meyer.